Skye (SKYE) Q2 R&D Soars 249% No Revenue

Skye Bioscience (NASDAQ:SKYE), a biotechnology company developing novel obesity therapeutics, released its second quarter earnings on August 7, 2025. As in prior quarters, no commercial revenue was reported. Research and development expenses (GAAP) increased sharply, leading to a higher net loss (GAAP) and a notable reduction in cash and short-term investments compared to December 31, 2024. The absence of sales is expected for a pre-commercial stage biotech. Compared with prior periods and expectations, the quarter showed continued pipeline progress but significantly increased cash burn and operating losses. Source: Analyst estimates for the quarter provided by FactSet. Skye Bioscience is a pre-commercial biotechnology firm working to develop drug candidates that address unmet needs in metabolic diseases. Its main focus is nimacimab, a novel antibody that modulates the peripheral CB1 receptor, which is thought to help regulate key metabolic functions related to obesity and overweight.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool